Bokhyun Song, Subi Oh, Doyun Kim, Young Sang Cho, Il Joon Moon
{"title":"Changes in Revision Cochlear Implantation and Device Failure Profiles","authors":"Bokhyun Song, Subi Oh, Doyun Kim, Young Sang Cho, Il Joon Moon","doi":"10.21053/ceo.2023.00010","DOIUrl":null,"url":null,"abstract":"Objective. With rapid innovation in and expanding indications for cochlear implantation (CI), changes in the features of revision CI (RCI) appear to be emerging. This study aims to investigate the changes in RCI profile and discuss their clinical significance. Methods. A retrospective chart review was performed for all CIs performed at a tertiary medical institution between October 2001 and January 2023. The rate and reasons for RCI were evaluated and examined in terms of the manufacturer and device model. The Kaplan-Meier curve was used to examine the cumulative and device survival curves. In addition, the cumulative and device survivals were further analyzed based on age group, time period of primary CI, and manufacturer. Cox proportional hazards model was used to evaluate the association between RCI and manufacturers. Results. Among 1,430 CIs, 73 RCIs were conducted (5.1%). Device failure was the most common cause of RCI (40 of 73 RCIs [54.8%]), with an overall device failure rate of 2.8%, followed by flap-associated problems and migration (9 of 73 RCIs each [12.3%]). Flap retention problem appeared as a new cause in three cases (two CI 632 and one SYNCHRONY 2), and six electrode tip fold-over occurred (four CI 600 series and two CI 500 series). The 10-year overall cumulative and device survival rates were 93.4% and 95.8%, respectively. After excluding the models with recall issues, cumulative (P= 0.010) and device survival curves ( P= 0.001) revealed significant differences by manufacturer.","PeriodicalId":10318,"journal":{"name":"Clinical and Experimental Otorhinolaryngology","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Otorhinolaryngology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21053/ceo.2023.00010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective. With rapid innovation in and expanding indications for cochlear implantation (CI), changes in the features of revision CI (RCI) appear to be emerging. This study aims to investigate the changes in RCI profile and discuss their clinical significance. Methods. A retrospective chart review was performed for all CIs performed at a tertiary medical institution between October 2001 and January 2023. The rate and reasons for RCI were evaluated and examined in terms of the manufacturer and device model. The Kaplan-Meier curve was used to examine the cumulative and device survival curves. In addition, the cumulative and device survivals were further analyzed based on age group, time period of primary CI, and manufacturer. Cox proportional hazards model was used to evaluate the association between RCI and manufacturers. Results. Among 1,430 CIs, 73 RCIs were conducted (5.1%). Device failure was the most common cause of RCI (40 of 73 RCIs [54.8%]), with an overall device failure rate of 2.8%, followed by flap-associated problems and migration (9 of 73 RCIs each [12.3%]). Flap retention problem appeared as a new cause in three cases (two CI 632 and one SYNCHRONY 2), and six electrode tip fold-over occurred (four CI 600 series and two CI 500 series). The 10-year overall cumulative and device survival rates were 93.4% and 95.8%, respectively. After excluding the models with recall issues, cumulative (P= 0.010) and device survival curves ( P= 0.001) revealed significant differences by manufacturer.
期刊介绍:
Clinical and Experimental Otorhinolaryngology (Clin Exp Otorhinolaryngol, CEO) is an international peer-reviewed journal on recent developments in diagnosis and treatment of otorhinolaryngology-head and neck surgery and dedicated to the advancement of patient care in ear, nose, throat, head, and neck disorders. This journal publishes original articles relating to both clinical and basic researches, reviews, and clinical trials, encompassing the whole topics of otorhinolaryngology-head and neck surgery.
CEO was first issued in 2008 and this journal is published in English four times (the last day of February, May, August, and November) per year by the Korean Society of Otorhinolaryngology-Head and Neck Surgery. The Journal aims at publishing evidence-based, scientifically written articles from different disciplines of otorhinolaryngology field.
The readership contains clinical/basic research into current practice in otorhinolaryngology, audiology, speech pathology, head and neck oncology, plastic and reconstructive surgery. The readers are otolaryngologists, head and neck surgeons and oncologists, audiologists, and speech pathologists.